CKM Guideline Sets Staged Risk and Atherogenic Goals

Risk assessment now starts with CKM stage

The guideline reorganizes lipid assessment around cardiovascular-kidney-metabolic syndrome. Cholesterol, diabetes, obesity and chronic kidney disease no longer sit in separate risk silos. Clinicians are asked to establish a CKM stage before estimating cardiovascular risk and choosing lipid goals.

Stage 0 describes people without CKM risk factors. Stage 1 covers excess or dysfunctional adiposity without established metabolic abnormalities or kidney disease. Stage 2 includes metabolic risk factors or chronic kidney disease. Stage 3 means subclinical cardiovascular disease in the CKM setting, while stage 4 means clinical cardiovascular disease, with an added distinction for kidney failure.

That sequence matters. Conventional short-term estimates can understate risk in younger adults and in people with diabetes, albuminuria or impaired kidney function, and CKM staging puts those conditions on the page before anyone opens a calculator. It also identifies stage 3 or 4 disease, where management should not be reduced to a primary-prevention percentage.

I wrote the stages down the left side of the notebook. The progression looks tidy there. Real patients may move between categories or arrive with missing kidney data, an old lipid panel and no urine albumin result.

The framework is not a trial intervention. The guideline draws together evidence and expert judgment, but it does not report a randomized comparison showing that CKM staging improves cardiovascular outcomes. Its immediate value is organizational: clinicians get one pathway for overlapping metabolic, kidney and cardiovascular risks.

PREVENT-ASCVD replaces the older risk framework

For adults without known atherosclerotic cardiovascular disease, the guideline adopts the AHA PREVENT-ASCVD equations instead of the pooled cohort equations. PREVENT was developed for US adults ages 30 to 79. It estimates 10-year risk, and a 30-year estimate may help frame discussions for eligible younger adults.

The equations are sex-specific and do not use race as a predictor. They draw on age, blood pressure, cholesterol, body mass index and diabetes status, along with smoking, relevant treatment and estimated glomerular filtration rate. Urine albumin-to-creatinine ratio, hemoglobin A1c and a measure of social deprivation can refine the estimate when those data are available.

PREVENT was derived and externally validated with electronic health record data from more than 6 million adults across its development and validation cohorts. That research tested calibration and discrimination, meaning how well the model’s estimates matched observed risk and separated people at different levels of risk; it did not test whether treatment decisions made with PREVENT avert more events than decisions made with another calculator.

The actionable 10-year categories are low risk below 3%, borderline risk from 3% to below 5%, intermediate risk from 5% to below 10%, and high risk at 10% or greater. Those numbers need context. CKM stage may change how a clinician reads them. So can lifetime exposure to atherogenic lipoproteins, a risk-enhancing condition or evidence of subclinical atherosclerosis.

On the notebook page, I left space between the risk percentage and the lipid goals. That gap is where the judgment sits.

Health systems have more work to do than swapping one calculator link for another. Electronic records need current eGFR, usable blood pressure readings and accurate medication information, while pathways for albuminuria must bring kidney findings into the estimate rather than leaving them in a disconnected lab result. Missing kidney data could weaken assessment most in patients who already face barriers to preventive care.

Explicit lipid goals return to the center of care

The guideline makes LDL cholesterol the primary treatment target and supplies corresponding goals for non-HDL cholesterol and apoB. The additional measures can help when LDL-C does not fully represent the number or cholesterol content of circulating atherogenic particles.

The principal goals are:

The table is the most crowded part of my notebook. It is also easy to overread. These goals do not replace attention to percentage LDL-C reduction, treatment response or adverse effects, and they do not erase adherence or patient preferences. A calculated risk above a threshold does not send every patient into the same regimen.

Established cardiovascular disease and severe hypercholesterolemia have their own implications. Diabetes, chronic kidney disease and subclinical atherosclerosis also have to be interpreted through the recommendations that apply to those conditions.

Non-HDL-C comes from the standard lipid panel by subtracting HDL-C from total cholesterol. It includes cholesterol carried in LDL and other apoB-containing particles, and it remains interpretable with elevated triglycerides. ApoB more directly reflects the concentration of atherogenic particles, though the guideline treats it as an optional test rather than a universal replacement for LDL-C.

ApoB is most useful when particle number and LDL-C may disagree, as can happen with hypertriglyceridemia, diabetes or obesity, or when risk remains elevated despite an apparently acceptable LDL-C. Coverage and availability vary. If health systems adopt apoB goals, reporting and reimbursement will matter, as will clinical support that keeps access to the test from depending mainly on a patient’s insurance or ZIP code.

Lp(a) becomes a routine once-in-adulthood measurement

The guideline recommends measuring lipoprotein(a) at least once during adulthood. Lp(a) is largely genetically determined, so one result will generally establish inherited risk unless a major inflammatory, kidney or other clinical change complicates interpretation.

An Lp(a) concentration of at least 125 nmol/L or 50 mg/dL counts as a risk-enhancing level. The units cannot be converted with a fixed ratio because particle composition varies. Laboratories should report the unit they measured. A high result can support more intensive management of modifiable risk factors, but it does not establish clinical ASCVD.

I put “once” beside Lp(a) in the notebook, then underlined the unit issue. A result can follow someone for years only if later clinicians can find it.

That is the practical challenge. One-time testing has limited value when a result is buried in the record, repeated without a reason or missing from the view used for future treatment decisions. Structured lab fields and durable documentation could help. Coverage without restrictive prerequisites would make the recommendation more usable.

Important uncertainties remain

This is a guideline, not a randomized trial of CKM staging, PREVENT-guided treatment or lipid-goal implementation. Its thresholds combine observational risk prediction with lipid-lowering trial evidence and expert synthesis. No direct comparison has yet shown that this whole pathway produces better outcomes than the previous US approach.

PREVENT came from large, contemporary US datasets, but performance can still differ across health systems and among populations with sparse clinical information. Albuminuria often goes unmeasured. Social risk is incompletely recorded, and some very high-risk groups may be underrepresented. Access to apoB and Lp(a) testing also changes with geography, insurance and laboratory capacity.

The question of whether dedicated Lp(a)-lowering therapies reduce cardiovascular events remains separate. Until outcomes evidence and regulatory decisions answer it, an elevated result mainly refines risk and strengthens the case for addressing established modifiable factors.

There is a question mark in the notebook beside implementation. I left it there.

Questions clinicians ask

Who should receive a PREVENT-ASCVD estimate?

PREVENT-ASCVD is intended for adults ages 30 to 79 who do not have known cardiovascular disease. CKM staging comes first. Clinical ASCVD places a person in stage 4, while subclinical disease or advanced kidney risk may make a stand-alone primary-prevention percentage inadequate for a treatment decision.

Does every adult need apoB testing?

No. LDL-C remains the primary target, and non-HDL-C is already available from a standard lipid panel. ApoB is optional when triglycerides, diabetes, obesity or other factors may produce discordance between LDL-C and atherogenic particle number. It can also help when residual risk remains uncertain after treatment.

How often should Lp(a) be measured?

For most adults, once in a lifetime is enough because Lp(a) is predominantly inherited and usually stable. Repeat testing may be reasonable if the first measurement occurred during a condition that could affect interpretation. Routine serial measurement is not the guideline’s central recommendation.

Do the lipid goals dictate one drug or treatment sequence?

No. The goals describe intended atherogenic-lipid levels. Therapy selection still depends on baseline risk and CKM stage, along with prior cardiovascular disease, treatment response, tolerability and patient preferences. The evidence supports reducing exposure to atherogenic lipoproteins; a numeric goal does not replace individual clinical judgment.

At the bottom of the notebook page, the final table row still reads 55, 85 and 65.

Questions people ask

Who is the PREVENT-ASCVD calculator intended for?

The guideline uses PREVENT-ASCVD for adults ages 30 to 79 without known cardiovascular disease, after establishing CKM stage. I noted that subclinical disease, advanced kidney risk or clinical ASCVD can make a primary-prevention percentage insufficient on its own.

Does every adult need an apoB test?

No. LDL-C remains the primary target, while non-HDL-C is available from a standard lipid panel. I found that apoB is optional when diabetes, obesity or high triglycerides may create a mismatch between LDL-C and atherogenic particle number.

How often is Lp(a) measured under the guideline?

The guideline recommends measuring Lp(a) at least once during adulthood because it is largely inherited and usually stable. I underlined that its units cannot be converted using a fixed ratio and that repeat testing may be considered when the first result was affected by another clinical condition.

References

1. 2026 AHA/ACC/ADA/ASN Guideline for the Management of Dyslipidemia — American Heart Association and American College of Cardiology, 2026 2. Development and Validation of the American Heart Association’s PREVENT Equations — Circulation, 2024 3. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association — Circulation, 2023 4. 2018 Guideline on the Management of Blood Cholesterol: Executive Summary — Circulation, 2019